Microsomal Prostaglandin e Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 1, 2016, Pages 108-121

  Gao, Cheng ^a,c   Fu, Yi ^a,c   Li, Yanhui ^b,c   Zhang, Xu ^a,c   Zhang, Lu ^a,c   Yu, Fang ^a,c   Xu, Susanna S ^d   Xu, Qingbo ^e   Zhu, Yi ^a,c   Guan, Youfei ^a,c   Wang, Xian ^a,c   Kong, Wei ^a,c  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d GONVILLE AND CAIUS COLLEGE   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

adenine; calcium; myocardial infarction; phosphates; vascular calcification

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ADENINE; ALKALINE PHOSPHATASE; CALCIUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; CALCITRIOL; CYCLOOXYGENASE 2 INHIBITOR; ISOMERASE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN SYNTHASE; PTGER4 PROTEIN, RAT; PTGES PROTEIN, RAT; PTGS2 PROTEIN, MOUSE; PTGS2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; CELL TRANSDIFFERENTIATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR RING; VASCULAR SMOOTH MUSCLE CELL; ABDOMINAL AORTA; ANIMAL; AORTIC DISEASES; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; METABOLOMICS; NEPHRECTOMY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; THORACIC AORTA; TIME FACTOR; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

ADENINE; ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC DISEASES; CALCITRIOL; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY FAILURE, CHRONIC; MALE; METABOLOMICS; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEPHRECTOMY; PHOSPHATES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR CALCIFICATION;

EID: 84952639717     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306642     Document Type: Article

References (48)

1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 1092 1102. doi: 10.1056/NEJMoa050493
2. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P, Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011 342 c7086
3. Zhang J, Ding EL, Song Y, Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006 296 1619 1632. doi: 10.1001/jama.296.13.jrv60015
4. Fitzgerald GA, Coxibs and cardiovascular disease. N Engl J Med 2004 351 1709 1711. doi: 10.1056/NEJMp048288
5. Samuelsson B, Morgenstern R, Jakobsson PJ, Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007 59 207 224. doi: 10.1124/pr.59.3.1
6. Wang M, FitzGerald GA, Cardiovascular biology of microsomal prostaglandin E synthase-1. Trends Cardiovasc Med 2010 20 189 195. doi: 10.1016/j.tcm.2011.04.002
7. Demer LL, Tintut Y, Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008 117 2938 2948. doi: 10.1161/CIRCULATIONAHA.107.743161
8. Sage AP, Tintut Y, Demer LL, Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010 7 528 536. doi: 10.1038/nrcardio.2010.115
9. Johnson RC, Leopold JA, Loscalzo J, Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006 99 1044 1059. doi: 10.1161/01.RES.0000249379.55535.21
10. Tian XY, Zhang Q, Zhao R, Setterberg RB, Zeng QQ, Iturria SJ, Ma YF, Jee WS, Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats. Bone 2008 42 914 920. doi: 10.1016/j.bone.2007.12.228
11. Blackwell KA, Raisz LG, Pilbeam CC, Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010 21 294 301. doi: 10.1016/j.tem.2009.12.004
12. Nakalekha C, Yokoyama C, Miura H, Alles N, Aoki K, Ohya K, Morita I, Increased bone mass in adult prostacyclin-deficient mice. J Endocrinol 2010 204 125 133. doi: 10.1677/JOE-09-0376
13. Casado-Díaz A, Santiago-Mora R, Dorado G, Quesada-Gómez JM, The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis. Osteoporos Int 2013 24 1647 1661. doi: 10.1007/s00198-012-2138-z
14. Rios A, Vargas-Robles H, Gámez-Méndez AM, Escalante B, Cyclooxygenase-2 and kidney failure. Prostaglandins Other Lipid Mediat 2012 98 86 90. doi: 10.1016/j.prostaglandins.2011.11.004
15. Vogt L, Laverman GD, Navis G, Time for a comeback of NSAIDs in proteinuric chronic kidney disease? Neth J Med 2010 68 400 407
16. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, Otomo S, NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993 24 105 110
17. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC, Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998 95 13313 13318
18. Jia T, Olauson H, Lindberg K, Amin R, Edvardsson K, Lindholm B, Andersson G, Wernerson A, Sabbagh Y, Schiavi S, Larsson TE, A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol 2013 14 116. doi: 10.1186/1471-2369-14-116
19. Zhao Y, Zhao MM, Cai Y, Zheng MF, Sun WL, Zhang SY, Kong W, Gu J, Wang X, Xu MJ, Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation. Kidney Int 2015 88 711 721. doi: 10.1038/ki.2015.160
20. Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, Méthot N, Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem 2004 279 23229 23237. doi: 10.1074/jbc.M400443200
21. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, Zhang T, Wang Y, Wang X, Xu M, Luo GZ, Zhu Y, Xu Q, Wang X, Kong W, Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol 2012 32 2580 2588. doi: 10.1161/ATVBAHA.112.300206
22. Zhu S, Xue R, Zhao P, Fan FL, Kong X, Zheng S, Han Q, Zhu Y, Wang N, Yang J, Guan Y, Targeted disruption of the prostaglandin E2 E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice. Arterioscler Thromb Vasc Biol 2011 31 1739 1747. doi: 10.1161/ATVBAHA.111.226142
23. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA, COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005 96 1240 1247. doi: 10.1161/01.RES.0000170888.11669.28
24. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA, Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002 296 539 541. doi: 10.1126/science.1068711
25. Liu JY, Li N, Yang J, Li N, Qiu H, Ai D, Chiamvimonvat N, Zhu Y, Hammock BD, Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci USA 2010 107 17017 17022. doi: 10.1073/pnas.1011278107
26. Gkaliagkousi E, Gavriilaki E, Doumas M, Petidis K, Aslanidis S, Stella D, Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol 2012 18 422 430. doi: 10.1097/RHU.0b013e31827846b1
27. Paccou J, Brazier M, Mentaverri R, Kamel S, Fardellone P, Massy ZA, Vascular calcification in rheumatoid arthritis: prevalence, pathophysiological aspects and potential targets. Atherosclerosis 2012 224 283 290. doi: 10.1016/j.atherosclerosis.2012.04.008
28. Bea F, Blessing E, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J, Rosenfeld ME, Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 2003 60 198 204
29. Wu M, Rementer C, Giachelli CM, Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013 93 365 373. doi: 10.1007/s00223-013-9712-z
30. Chen L, Yang G, Monslow J, Todd L, Cormode DP, Tang J, Grant GR, DeLong JH, Tang SY, Lawson JA, Pure E, Fitzgerald GA, Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc Natl Acad Sci USA 2014 111 6828 6833. doi: 10.1073/pnas.1401797111
31. Wang M, Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, Grant G, Cheng Y, Lawson JA, Assoian RK, Jones PL, Fitzgerald GA, Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury. Circulation 2011 123 631 639. doi: 10.1161/CIRCULATIONAHA.110.973685
32. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, Puré E, FitzGerald GA, Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 2008 117 1302 1309. doi: 10.1161/CIRCULATIONAHA.107.731398
33. Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E, FitzGerald GA, Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006 103 14507 14512. doi: 10.1073/pnas.0606586103
34. Wang M, Song WL, Cheng Y, Fitzgerald GA, Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 2008 263 500 505. doi: 10.1111/j.1365-2796.2008.01938.x
35. Chen L, Yang G, Xu X, Grant G, Lawson JA, Bohlooly YM, FitzGerald GA, Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation 2013 127 233 243. doi: 10.1161/CIRCULATIONAHA.112.119479
36. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A, Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001 104 921 927
37. Swan CE, Breyer RM, Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models. Prostaglandins Other Lipid Mediat 2011 96 10 13. doi: 10.1016/j.prostaglandins.2011.07.001
38. Hasan D, Hashimoto T, Kung D, Macdonald RL, Winn HR, Heistad D, Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results. Stroke 2012 43 1964 1967. doi: 10.1161/STROKEAHA.112.655829
39. 2 promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 2013 113 104 114. doi: 10.1161/CIRCRESAHA.113.301033
40. Manokawinchoke J, Pimkhaokhum A, Everts V, Pavasant P, Prostaglandin E2 inhibits in-vitro mineral deposition by human periodontal ligament cells via modulating the expression of TWIST1 and RUNX2. J Periodontal Res 2014 49 777 784. doi: 10.1111/jre.12162
41. McCarthy TL, Ji C, Chen Y, Kim KK, Imagawa M, Ito Y, Centrella M, Runt domain factor (Runx)-dependent effects on CCAAT/enhancer-binding protein delta expression and activity in osteoblasts. J Biol Chem 2000 275 21746 21753. doi: 10.1074/jbc.M002291200
42. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T, The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000 141 1554 1559. doi: 10.1210/endo.141.4.7405
43. Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T, Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000 275 19819 19823. doi: 10.1074/jbc.M002079200
44. Oka H, Miyauchi M, Sakamoto K, Kitagawa M, Noguchi K, Somerman MJ, Takata T, Prostaglandin E2 inhibits mineralization and enhances matrix metalloproteinase-13 in mature cementoblasts mainly via the EP4 pathway. Arch Oral Biol 2008 53 243 249. doi: 10.1016/j.archoralbio.2007.10.007
45. Wirrig EE, Gomez MV, Hinton RB, Yutzey KE, COX2 inhibition reduces aortic valve calcification in vivo. Arterioscler Thromb Vasc Biol 2015 35 938 947. doi: 10.1161/ATVBAHA.114.305159
46. Pawade TA, Newby DE, Dweck MR, Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol 2015 66 561 577. doi: 10.1016/j.jacc.2015.05.066
47. Ruiz JL, Hutcheson JD, Aikawa E, Cardiovascular calcification: current controversies and novel concepts. Cardiovasc Pathol 2015 24 207 212. doi: 10.1016/j.carpath.2015.03.002
48. Tanaka T, Sato H, Doi H, Yoshida CA, Shimizu T, Matsui H, Yamazaki M, Akiyama H, Kawai-Kowase K, Iso T, Komori T, Arai M, Kurabayashi M, Runx2 represses myocardin-mediated differentiation and facilitates osteogenic conversion of vascular smooth muscle cells. Mol Cell Biol 2008 28 1147 1160. doi: 10.1128/MCB.01771-07